| dbo:abstract
|
- Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs including:
* Tanezumab (codenamed RN624), a monoclonal antibody against nerve growth factor for the treatment of pain
* Ponezumab (codenamed RN1219), a monoclonal antibody against Beta amyloid for the treatment of Alzheimer's disease
* Fremanezumab (codenamed TEV-48125, RN307 and LBR-101), a monoclonal antibody against Calcitonin gene-related peptide for the treatment of migraines
* Bococizumab (codenamed RN316), a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
* RN6G, a monoclonal antibody against Beta amyloid for the treatment of Geographic Atrophy in Age-Related Macular Degeneration
* RN909, a monoclonal antibody antagonist of the glucagon receptor for type 2 diabetes (T2DM)
* REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer
* PF-04518600 a monoclonal antibody targeting OX40 to enhance T cell functions and inhibit tumor growth Rinat was founded in 2001 by Arnon Rosenthal, who was also Rinat's president, chief scientific office and board director, and Patrick Lynn, following a broad licensing agreement with Genentech, and was acquired by Pfizer in 2006 for approximately $500M. Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco. (en)
|
| dbo:country
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 6766 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs including:
* Tanezumab (codenamed RN624), a monoclonal antibody against nerve growth factor for the treatment of pain
* Ponezumab (codenamed RN1219), a monoclonal antibody against Beta amyloid for the treatment of Alzheimer's disease
* Fremanezumab (codenamed TEV-48125, RN307 and LBR-101), a monoclonal antibody against Calcitonin gene-related peptide for the treatment of migraines
* Bococizumab (codenamed RN316), a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
* RN6G, a monoclonal antibody against Beta amyloid for the treatment of Geographic Atrophy in Age-Related Macular Degeneration
* RN909, a monoclonal antibody antagonist of the gl (en)
|
| rdfs:label
|
- Rinat Neuroscience Corporation (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:institution
of | |
| is dbo:knownFor
of | |
| is dbo:wikiPageWikiLink
of | |
| is dbp:workplaces
of | |
| is foaf:primaryTopic
of | |
